Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial
| Autor: | Willem Daniel Francois, Venter, Andrew, Kambugu, Matthew F, Chersich, Stephen, Becker, Andrew, Hill, Natasha, Arulappan, Michelle, Moorhouse, Mohammed, Majam, Godspower, Akpomiemie, Simiso, Sokhela, Selvamuthu, Poongulali, Charles, Feldman, Chris, Duncombe, David H Brown, Ripin, Alinda, Vos, Nagalingeswaran, Kumarasamy |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Anti-HIV Agents stavudine DEXA India resource allocation HIV Infections Equivalence Trials as Topic Kidney Bone and Bones South Africa Young Adult Double-Blind Method Humans Uganda Tenofovir public health HIV toxicity Clinical Science trial Stavudine dose reduction ComputingMethodologies_DOCUMENTANDTEXTPROCESSING Female renal |
| Zdroj: | Journal of Acquired Immune Deficiency Syndromes (1999) |
| ISSN: | 1944-7884 |
| Popis: | Supplemental Digital Content is Available in the Text. Background: Reducing doses of antiretroviral drugs, including stavudine (d4T), may lower toxicity, while preserving efficacy. There are substantial concerns about renal and bone toxicities of tenofovir disoproxil fumarate (TDF). Setting: HIV-1–infected treatment-naive adults in India, South Africa, and Uganda. Methods: A phase-4, 96-week, randomized, double-blind, noninferiority trial compared d4T 20 mg twice daily and TDF, taken in combination with lamivudine (3TC) and efavirenz (EFV). The primary endpoint was the proportion of participants with HIV-1 RNA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|